November 2025

Literature review thumbnail: PsA Literature Highlights - November 2025

PsA Literature Highlights - November 2025

more…

Keywords:

  • Upadacitinib; Psoriatic arthritis; Oligoarticular psoriatic arthritis; Polyarticular psoriatic arthritis; Effectiveness; Minimal disease activity; Very low disease activity; Remission, Psoriatic arthritis, Bdmard, Tsdmard, Biologic, Inflammatory arthritis, 4 th line,janus kinase inhibitors, tumor necrosis factor inhibitors, uveitis, autoimmune disease, TriNetX, cohort study.

    • October 2025

    Literature review thumbnail: Sonelokimab, an IL-17A- and IL-17F- inhibiting nanobody for active psoriatic arthritis: A randomized, placebo-controlled Phase 2 trial

    Sonelokimab, an IL-17A- and IL-17F- inhibiting nanobody for active psoriatic arthritis: A randomized, placebo-controlled Phase 2 trial

    In this first global clinical study of a nanobody in inflammatory arthritis, sonelokimab, an
    IL-17A- and IL-17F-inhibiting nanobody demonstrated strong efficacy across multiple domains including high-hurdle composite joint and skin responses. McInnes et al. reported on the Phase 2, randomized, double-blind, PBO-controlled ARGO trial which evaluated the efficacy and safety of sonelokimab in patients with active PsA.

    more…

    Keywords:

  • Efficacy, IL-17, Phase 2, Safety, Skin

    • September 2025